Control group:Toripalimab plus chemotherapy

2 trials

Sponsors

The First Affiliated Hospital of Zhengzhou University, Shanghai Pulmonary Hospital

Conditions

Esophageal cancerSurgically resectable or potentially resectable stage II–III NSCLC

Phase 3

Anlotinib plus bemipalimab versus toripalimab plus chemotherapy as first-line therapy in patients with advanced esophageal squamous cell carcinoma harboring specific gene mutations: a randomized, open-label, parallel-group, multicenter, phase III trial

RecruitingChiCTR2600129030

The First Affiliated Hospital of Zhengzhou UniversityEsophageal cancer

Start: 2026-03-23Updated: 2026-08-03

Phase 4

A Randomized, Controlled, Multicenter Phase III Clinical Study of Spatial Fractionated SBRT Combined with Toripalimab Plus Chemotherapy versus Toripalimab Plus Chemotherapy for Resectable or Potentially Resectable Stage II–III Non-Small Cell Lung Cancer (NSCLC)

Active, not recruitingChiCTR2600129470

Shanghai Pulmonary HospitalSurgically resectable or potentially resectable stage II–III NSCLC

Start: 2026-08-17Updated: 2026-08-10